Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acumen Pharmaceuticals Inc
NASDAQ ABOS
Data sourced from
and
and
Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: 0.25
Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio is 0.25 for the Trailing 12 Months (TTM) ending March 31, 2024, a -97.49% change year over year. The net debt to EBITDA ratio measures the level of a company's net debt relative to its earnings before interest, taxes, depreciation, and amortization (EBITDA). It is calculated by dividing the net debt (total debt minus cash and cash equivalents) by EBITDA. This ratio provides insights into the company's ability to repay its debt using its operating earnings. A higher ratio indicates a higher level of debt relative to earnings, suggesting potential financial risk and difficulty in debt repayment.
-
Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 9.93, a -9.58% change year over year.
-
Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 10.98, a -28.00% change year over year.
-
Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 15.24.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ABOS
| CEO | Mr. Daniel J. O'Connell M.B.A. |
| IPO Date | July 1, 2021 |
| Location | United States |
| Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email